To the content
4 . 2022

New national medical acceptance criteria for methods of contraception (2022): contribution to women’s reproductive health

Abstract

Medical activity and development of medical science must keep in step with the tasks of the state: birth of healthy children and fight against abortion through rational and effective contraception usage aimed at protecting the reproductive health of women, planning and giving birth to a desired healthy child, and therefore preserving the future of our nation. In relation to the contraception problem, the progress of its development determined the idea and creation of modern drugs with new contraceptive, therapeutic and prophylactic properties, which made it possible to reduce the adverse effect of some compounds on the woman’s body. This is most important in relation to the effect of drugs on metabolic processes, the hemostasis system, and not only. Based on a detailed analysis, this review identifies the positive effects of well-known, long-used drugs and newly created compounds on women’s reproductive health.

Keywords:contraception; combined oral contraceptives; women’s reproductive health; abortion; fertility

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Prilepskaya V.N., Mezhevitinova E.A., Nazarova N.M., Yakushevskaya O.V., Aganezova N.V., Chernukha G.E., Kepsha M.A. New national medical acceptance criteria for methods of contraception (2022): contribution to women’s reproductive health. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2022; 10 (4): 53–60. DOI: https://doi.org/10.33029/2303-9698-2022-10-4-53-60 (in Russian)

REFERENCES

1. Ulumbekova G.E., Ginoyan A.B., Khudova I.Yu. Scientific substantiation of the conditions for increasing the birth rate in the Russian Federation in the period from 2022 to 2030. ORGZDRAV: novosti, mneniya, obuchenie. Vestnik VShOUZ [ORGZDRAV: News, Opinions, Training. Bulletin of VShOUZ]. 2022; 8 (1): 4–22. DOI: https://doi.org/10.33029/2411-8621-2022-8-1-4-22 (in Russian)

2. Smelov P.A., et al. Women and men of Russia. 2020: Statistical collection. In: Rosstat. Moscow, 2020: 239 p. (in Russian)

3. Federal State Statistics Service. Brief report on the results of the sample survey «Reproductive health survey Russia 2011». URL: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/healthcare (in Russian)

4. Rosstat data, 2017. URL: http://www.gks.ru/free_doc/doc_2017/zdrav17.pdf (in Russian)

5. Zhang L., Zetter M.A., Guerra E.C., Hernández V.S., Mahata S.K., Eiden L.E. ACE2 in the second act of COVID-19 syndrome: peptide dysregulation and possible correction with oestrogen. J Neuroendocrinol. 2021; 33: e12935. DOI: https://doi.org/10.1111/jne.12935

6. Makatsariya A.D., Slukhanchuk E.V., Bitsadze V.O., Khizroeva J.K., Tret’ya- kova M.V., Tsibizova V.I., et al. COVID-19, hemostasis disorders and risk of thrombotic complications. Vestnik RAMN [Bulletin of the Russian Academy of Medical Sciences]. 2020; 75 (4): 306–17. DOI: https://doi.org/10.15690/vramn1368 (in Russian)

7. Cagnacci A., Londero A.P., Xholli A. COVID-19 and hormonal contraception. Case Rep Womens Health. 2022; 34: e00389. DOI: https://doi.org/10.1016/j.crwh.2022.e00389 Epub 2022 Jan 25. PMID: 35096531; PMCID: PMC8788094.

8. Ali M., Akin A., Bahamondes L., Brache V., Habib N., Landoulsi S., et al.; WHO Study Group on Subdermal Contraceptive Implants for Women. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016; 31 (11): 2491–8.

9. Foran T., Butcher B.E., Kovacs G., Bateson D., O’Connor V. Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: a systematic review. Eur J Contracept Reprod Health Care. 2018; 23 (5): 379–86.

10. Limanova O.A., Torshin I.Yu., Sardaryan I.S., et al. Micronutrient provision and women’s health: intellectual analysis of clinicoepidemiological data. Voprosy ginekologii, akusherstva i perinatologii [Problems of Gynecology, Obstetrics and Perinatology]. 2014; 13 (2): 5–15. (in Russian)

11. Prilepskaya V.N., Bostandzhyan L.L. Folate contraception and clinical practice. Ginekologiya [Gynecology]. 2020; 22 (6): 101–7. (in Russian)

12. Normal pregnancy. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow, 2020. (in Russian)

13. Arya R., et al. J Neonatol. 2006; 20 (4): 316–26.

14. Taylor T.N., Farkouh R.A., Graham J.B., Colligs A., Lindemann M., Lynen R., et al. Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States. Am J Obstet Gynecol. 2011; 205 (5): 460.e1–8.

15. Food & Drug Administration. URL: http://www.fda.gov/ohrms/dockets/ac/03/minutes/4002M1_Final.pdf

16. Cheschier N.; ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Neural tube defects. No. 44, July 2003. (Replaces committee opinion No. 252, March 2001). Int J Gynaecol Obstet. 2003; 83 (1): 123–33.

17. Am J Clin Nutr. 2003; 77 (4): 757–9.

18. De Batlle J., et al. Dietary folate intake and breast cancer risk: European prospective investigation into cancer and nutrition. J Natl Cancer Inst. 2014; 107 (1): 367.

19. Prilepskaya V.N. Contraception with folates and real clinical practice. All-Russian Scientific and Educational Forum «Mother and Child». Effektivnaya farmakoterapiya. Akusherstvo i ginekologiya. [Effective Pharmacotherapy. Obstetrics and Gynecology]. 2018; (3–4): 36–44. (in Russian)

20. Prilepskaya V.N., Dovletkhanova E.R. Hormonal contraception using a combined oral contraceptive containing estradiol valerate/dienogest. Meditsinskiy opponent [Medical Opponent]. 2022; 2 (18): 46–52. (in Russian)

21. Dinger J., Möhner S., Heinemann K. Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: results from the extended INAS-SCORE study. Front Womens Health. 2020; 5: 1–8.

22. Prilepskaya V.N., Mezhevitinova E.A., Nazarenko E.G., Gorodnova E.A. The renaissance of barrier contraception (based on the data from an international clinical trial). Ginekologiya [Gynecology]. 2021; 23 (5): 380–5. DOI: https://doi.org/10.26442/20795696.2021.5.201151 (in Russian)

23. Gollub E. Women’s barrier contraceptive methods as modern methods. Sex Health. 2011; 8 (1): 128–9.

24. Minnis A.M., Padian N.S. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect. 2005; 81 (3): 193–200.

25. Tussell J. Contraceptive failure in the United States. Contraception. 2011; 83 (5): 397–404. DOI: https://doi.org/10.1016/j.contraception.2011.01.021

26. Raymond E.G., Chen P.L., Luoto J.; Spermicide Trial Group. Contraceptive effectiveness and safety of five nonoxynol-9 spermecides. A randomized trial. Obstet Gynecol. 2004; 103 (3): 430–9.

27. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP); Knowledge for Health Project. Family Planning: A Global Handbook for Providers (2018update). Baltimore and Geneva: CCP and WHO, 2018.

28. Serfaty D., Prilepskaya V., Graeslin O., et al. Contraceptive efficacy, tolerance and acceptability of a benzalkonium chloride spermicide cream in women aged over 40 years of age: interim results from a six-month, international, open-label, multicentre phase IV study. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2020; (4): 6–7. (in Russian)

29. Serfaty D. Contraception des femmes allaitantes: place des spermicides [Contraception in breastfeeding women: place for spermicides]. J Gynecol Obstet Biol Reprod (Paris). 2015; 44 (1): 18–27.

30. Johns Hopkins University. URL: https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6

31. Lete I. Combined hormonal contraception and COVID-1. Eur J Contracept Reprod Health Care. 2021; 26 (2): 128–31.

32. Hannaford P.C., Iversen L., Macfarlane T.V., Elliott A.M., Angus V., Lee A.J. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ. 2010; 340: c927.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITORS
CHIEF EDITOR
Sukhikh Gennadii Tikhonovich
Academician of the Russian Academy of Medical Sciences, V.I. Kulakov Obstetrics, Gynecology and Perinatology National Medical Research Center of Ministry of Healthсаre of the Russian Federation, Moscow
CHIEF EDITOR
Kurtser Mark Arkadievich
Academician of the Russian Academy of Sciences, MD, Professor, Head of the Obstetrics and Gynecology Subdepartment of the Pediatric Department, N.I. Pirogov Russian National Scientific Research Medical University, Ministry of Health of the Russian Federation
CHIEF EDITOR
Radzinsky Viktor Evseevich
Corresponding Member of the Russian Academy of Sciences, MD, Professor, Head of the Subdepartment of Obstetrics and Gynecology with a Course of Perinatology of the Medical Department in the Russian People?s Friendship University

Journals of «GEOTAR-Media»